• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

BAF57 expression of ovarian cancer cells and drug sensitivity
This article is protected by copyright. All rights reserved.
Source: Cancer Science - January 22, 2015 Category: Cancer & Oncology Authors: Takahiro Yamaguchi, Tomoko Kurita, Kazuto Nishio, Junichi Tsukada, Toru Hachisuga, Yasuo Morimoto, Yoshiko Iwai, Hiroto Izumi Tags: Original Article Source Type: research

Progestin and antiprogestin responsiveness in breast cancer is driven by the PRA/PRB ratio via AIB1 or SMRT recruitment to the CCND1 and MYC promoters
Abstract There is emerging interest in understanding the role of progesterone receptors (PRs) in breast cancer. The aim of this study was to investigate the proliferative effect of progestins and antiprogestins depending on the relative expression of the A (PRA) and B (PRB) isoforms of PR. In mifepristone (MFP)‐resistant murine carcinomas antiprogestin responsiveness was restored by re‐expressing PRA using demethylating agents and histone deacetylase inhibitors. Consistently, in two human breast cancer xenograft models, one manipulated to overexpress PRA or PRB (IBH‐6 cells), and the other expressing only PRA (T47D�...
Source: International Journal of Cancer - November 1, 2014 Category: Cancer & Oncology Authors: Victoria Wargon, Marina Riggio, Sebastián Giulianelli, Gonzalo R. Sequeira, Paola Rojas, María May, María L. Polo, María A. Gorostiaga, Britta Jacobsen, Alfredo Molinolo, Virginia Novaro, Claudia Lanari Tags: Cancer Therapy Source Type: research

Abstract 5203: Long non-coding RNA H19 as a novel therapeutic target for pancreatic cancer
Long non-coding RNAs (lncRNAs), non-protein coding transcripts longer than 200 nucleotides, have been recently reported to play important roles in carcinogenesis and cancer metastasis through epigenetic regulation. In the present study, we examined the expression levels and roles of lncRNA in pancreatic cancer to elucidate whether lncRNA could be a novel candidate for pancreatic cancer therapy. First, we injected PANC-1 and PK-45H, pancreatic ductal adenocarcinoma cells into the spleens of NOD/Shi-scid, IL-2Rγnull (NOG) mice, and then established novel cell lines from liver and lung metastatic nodules. Microarray analysis...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Yoshimura, H., Matsuda, Y., Suzuki, T., Naito, Z., Ishiwata, T. Tags: Molecular and Cellular Biology Source Type: research

Ziyuglycoside II induces cell cycle arrest and apoptosis through activation of ROS/JNK pathway in human breast cancer cells.
In this study, the anti-proliferative effect of ziyuglycoside II in two classic human breast cancer cell lines, MCF-7 and MDA-MB-231, was extensively investigated. Our study indicated that ziyuglycoside II could effectively induce G2/M phase arrest and apoptosis in both cell lines. Cell cycle blocking was associated with the down-regulation of Cdc25C, Cdc2, cyclin A and cyclin B1 as well as the up-regulation of p21/WAF1, phospho-Cdc25C and phospho-Cdc2. Ziyuglycoside II treatment also induced reactive oxygen species (ROS) production and apoptosis by activating the extrinsic/Fas/FasL pathway as well as the intrinsic/mitocho...
Source: Toxicology Letters - March 27, 2014 Category: Toxicology Authors: Zhu X, Wang K, Zhang K, Zhu L, Zhou F Tags: Toxicol Lett Source Type: research

Pages: 1  2